All‐cause mortality in adults · people with asthma
1 finding from 1 review
All‐cause mortality in children · people with asthma
1 finding from 1 review
All‐cause SAEs in adults · people with asthma
Regular formoterol showed no clear difference in all‐cause SAEs in adults compared with regular salmeterol (low certainty).
1 finding from 1 review
All‐cause SAEs in children · people with asthma
It is very uncertain whether regular formoterol changes all‐cause SAEs in children compared with regular salmeterol (very low certainty).
1 finding from 1 review
Asthma‐related SAE ‐ Adults · people with asthma
Regular formoterol showed no clear difference in asthma‐related SAEs in adults compared with regular salmeterol (low certainty).
1 finding from 1 review
Asthma‐related SAE ‐ Children · people with asthma
1 finding from 1 review
All‐cause mortality · adults, chronic asthma: all‐cause mortality
Regular formoterol and ICS showed no clear difference in all‐cause mortality compared with same‐dose ICS (moderate certainty).
1 finding from 1 review
Non‐fatal serious adverse events · adults, chronic asthma: all‐cause mortality
Regular formoterol and ICS showed no clear difference in all‐cause non‐fatal serious adverse events compared with same‐dose ICS (high certainty).
1 finding from 1 review
Asthma‐related mortality · adults, chronic asthma: all‐cause mortality
1 finding from 1 review
Asthma‐related non‐fatal serious adverse events · adults, chronic asthma: all‐cause mortality
Regular formoterol and ICS showed no clear difference in asthma‐related non‐fatal serious adverse events compared with same‐dose ICS (moderate certainty).
1 finding from 1 review
All‐cause mortality · children and adolescents with chronic asthma
1 finding from 1 review
Non‐fatal serious adverse events · children and adolescents with chronic asthma
Regular formoterol and ICS showed no clear difference in all‐cause non‐fatal serious adverse events compared with same‐dose ICS (moderate certainty).
1 finding from 1 review
Asthma‐related mortality · children and adolescents with chronic asthma
1 finding from 1 review
Asthma‐related non‐fatal serious adverse events · children and adolescents with chronic asthma
It is very uncertain whether regular formoterol and ICS changes asthma‐related non‐fatal serious adverse events compared with same‐dose ICS (very low certainty).
1 finding from 1 review